Video > Bladder Cancer Video Pearls Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer — Patients with complete response can have long treatment-free interval, study suggests ...

Secondary endpoints included duration of response (DoR), defined as the time from CR at 3 months to the earliest date of disease recurrence, progression, or death from any cause, whichever occurred ...

Of the 71 patients enrolled in OLYMPUS, 41 achieved a complete response after treatment with JELMYTO and had a median duration of response of 47.8 months (95% CI 13.0, not estimable), with median ...

Matulonis et al 1 conducted an important single-arm study to evaluate the efficacy and safety of mirvetuximab soravtansine for treating platinum-resistant ovarian cancer. The primary end point was ...

Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with JELMYTO (n=41, 20 of whom entered the long-term follow-up study), the median duration of ...

Adding Keytruda (pembrolizumab) to Lenvima (lenvatinib) led to better duration of response outcomes than Lenvima plus placebo in patients with advanced liver cancer (hepatocellular carcinoma; HCC), ...

In ENVISION, UGN-102 treatment was associated with an unprecedented 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) by Kaplan-Meier estimate (n=108) in patients who achieved ...